Showing papers on "Solid lipid nanoparticle published in 2000"
TL;DR: Relevant issues for the introduction of SLN to the pharmaceutical market, such as status of excipients, toxicity/tolerability aspects and sterilization and long-term stability including industrial large scale production are discussed.
3,260 citations
Patent•
22 Nov 2000
TL;DR: In this paper, solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered are presented. But they do not address the delivery of drugs, nutritional agents and diagnostic agents.
Abstract: The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compositions of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutritional agents, cosmeceuticals and diagnostic agents.
1,350 citations
TL;DR: The presented carrier of colloidal lipid particles with improved payloads and enhanced storage stability was investigated and adds additional benefits to the well-known opportunities of conventional SLN and is suited for topical use.
542 citations
TL;DR: Enhanced retinol palmitate uptake should derive from specific SLN effects and is not due to non-specific occlusive properties, as Transepidermal water loss (TEWL) and the influence of drug free SLN on retinyl palmitates uptake exclude pronounced Occlusive effects.
492 citations
TL;DR: The present study shows the great potential of SLN to improve drug absorption by the skin with penetration into human skin increased by 30% as compared to PC cream, permeation of reconstructed epidermis increased even 3-fold.
195 citations
TL;DR: In this article, a medium chain triglyceride oil was successfully incorporated in a matrix of a solid long chain glyceride (glyceryl behenate), and the resulting particles were solid but the oil inside the particle remained in a liquid state.
190 citations
TL;DR: The present study compares solid lipid nanoparticles (SLN) formulated with either wax or glyceride bulk material with respect to drug encapsulation efficacy, particle size distribution after production and storage, and crystal packing.
145 citations
TL;DR: It is demonstrated that, by optimizing critical process parameters, i.v.-injectable SLN-dispersions can be freeze-dried, preserving their small particle size.
121 citations
TL;DR: Rheological measurements of 40% lipid dispersions show viscoelastic properties comparable to the data from standard dermal preparations, and might constitute a promising vehicle for topical administration.
78 citations
TL;DR: In this paper, a new type of colloidal lipidic carrier is proposed: nanospheres of supercooled melts, which represent an intermediate state between emulsions and suspensions.
Abstract: Colloidal drug carriers offer a number of potential advantages as delivery systems for, for example, poorly soluble compounds. The first generation of colloidal carriers, in particular liposomes and sub-micron-sized lipid emulsions, are, however, associated with several drawbacks which so far have prevented the extensive use of these carriers in drug delivery. As an alternative colloidal delivery system melt-emulsified nanoparticles based on solid lipids have been proposed. Careful physicochemical characterization has demonstrated that these lipid-based nanosuspensions (solid lipid nanoparticles) are not just “emulsions with solidified droplets”. During the development process of these systems interesting phenomena have been observed, such as gel formation on solidification and upon storage, unexpected dynamics of polymorphic transitions, extensive annealing of nanocrystals over significant periods of time, stepwise melting of particle fractions in the lower-nanometer-size range, drug expulsion from the carrier particles on crystallization and upon storage, and extensive supercooling. These phenomena can be related to the crystalline nature of the carrier matrix in combination with its colloidal state. Observation of the supercooling effect has led to the development of a second new type of carrier system: nanospheres of supercooled melts. This novel type of colloidal lipidic carrier represents an intermediate state between emulsions and suspensions. Moreover, these dispersions are particularly suited to the study of the basic differences between colloidal triglyceride emulsions and suspensions. For many decades drug carriers have represented the only group of colloidal drug administration systems. Nowadays a fundamentally different group of dispersions is also under investigation: drug nanodispersions. They overcome a number of carrier-related drawbacks, such as limitations in drug load as well as side effects due to the matrix material of the carrier particles. Utilizing this concept virtually insoluble drugs can be formulated as colloidal particles, of solid or supercooled nature. For example, coenzyme Q10 (Q10) has been successfully processed into a dispersion of a supercooled melt. Droplet sizes in the lower nanometer range and shelf lives of more than 3 years can easily be achieved for Q10 dispersions. The drug load of the emulsion particles reaches nearly 100%.
77 citations
TL;DR: The influence of lipophilicity and structure of different SP on its location in SLN were studied and it was found that lipophilic SP distribute between a solid glyceride core and a soft phospholipid layer, with the more polar part oriented toward the water-lipid interface.
TL;DR: Preservation of SLN using thiomersal does not appear to cause increased cytotoxicity and immunomodulatory effects following incubation with Mpsi, and there were no synergistic cytotoxic effects of preservative and SLN.